Pubblicazioni

Autori:

Visco, Carlo; Di Rocco, Alice; Evangelista, Andrea; Quaglia, Francesca Maria; Tisi, Maria Chiara; Morello, Lucia; Zilioli, Vittorio Ruggero; Rusconi, Chiara; Hohaus, Stefan; Sciarra, Roberta; Re, Alessandro; Tecchio, Cristina; Chiappella, Annalisa; Marin-Niebla, Ana; Mcculloch, Rory; Gini, Guido; Perrone, Tommasina; Nassi, Luca; Pennese, Elsa; Stefani, Piero Maria; Cox, Maria Christina; Bozzoli, Valentina; Fabbri, Alberto; Polli, Valentina; Ferrero, Simone; Celis, Maria Isabel Alvarez De; Sica, Antonello; Petrucci, Luca; Arcaini, Luca; Rule, Simon; Krampera, Mauro; Vitolo, Umberto; Balzarotti, Monica

Titolo:

Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study

Anno:

2020

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

Leukemia

ISSN Rivista:

0887-6924

Intervallo pagine:

220-228

Parole chiave:

Mantle-First

Breve descrizione dei contenuti:

Patients with mantle cell lymphoma (MCL) that fail induction treatment represent a difficult-to-treat population, where no standard therapy exists. We evaluated outcomes in patients with first relapsed-refractory (r/r) MCL after upfront high dose cytarabine including standard regimens. Overall survival (OS-2) and progression-free survival (PFS-2) were estimated from the time of salvage therapy. The previously described threshold of 24 months was used to define patients as early- or late-progressors (POD). Overall, 261 r/r MCL patients were included. Second-line regimens consisted of rituximab-bendamustine (R-B, 21%), R-B and cytarabine (R-BAC, 29%), ibrutinib (19%), and others (31%). The four groups were balanced in terms of clinicopathological features. Adjusting for age and early/late-POD, patients treated with R-BAC had significantly higher complete remission (63%) than comparators. Overall, Ibrutinib and R-BAC were associated with improved median PFS-2 [24 and 25 months, respectively], compared to R-B (13) or others (7). In patients with early-POD (n = 127), ibrutinib was associated with inferior risk of death than comparators (HR 2.41 for R-B, 2.17 for others, 2.78 for R-BAC). In patients with late-POD (n = 134), no significant differences were observed between ibrutinib and bendamustine-based treatments. Ibrutinib was associated with improved outcome in early-POD patients.

Id prodotto:

116540

Handle IRIS:

11562/1026361

ultima modifica:

23 gennaio 2025

Citazione bibliografica:

Visco, Carlo; Di Rocco, Alice; Evangelista, Andrea; Quaglia, Francesca Maria; Tisi, Maria Chiara; Morello, Lucia; Zilioli, Vittorio Ruggero; Rusconi, Chiara; Hohaus, Stefan; Sciarra, Roberta; Re, Alessandro; Tecchio, Cristina; Chiappella, Annalisa; Marin-Niebla, Ana; Mcculloch, Rory; Gini, Guido; Perrone, Tommasina; Nassi, Luca; Pennese, Elsa; Stefani, Piero Maria; Cox, Maria Christina; Bozzoli, Valentina; Fabbri, Alberto; Polli, Valentina; Ferrero, Simone; Celis, Maria Isabel Alvarez De; Sica, Antonello; Petrucci, Luca; Arcaini, Luca; Rule, Simon; Krampera, Mauro; Vitolo, Umberto; Balzarotti, Monica, Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study «Leukemia» , 2020 , pp. 220-228

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo